تزريق داخل پروستات توکسين بوتولينيوم-A (BTX-A): روش درمانی جديد برای هايپرپلازی خوش¬خيم پروستات

Issa MM, Fenter TC, Black L, Grogg AL, Kruep EJ. An assessment of the diagnosed prevalence of diseases in men 50 years of age or older. Am J Manag Care 2006;12(4 Suppl):S83–S89.

McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term efficacy and safety study group. N Engl J Med 1998;338(9):557–563.

Schmidt RA. Urethrovesical reflexes and their inhibition. In: Hinman F, editors.‘Benign Prostatic Hypertrophy. New York: Springer-Verlag;1983.p.361–372.

Jankovic J, Brin MF: Therapeutic uses of botulinum toxin. N Engl J Med 1991;324(17):1186-1194.

Chuang YC, Chiang P, Hsien K, Yoshimura N, Demiguel F, Chancellor M. Beneficial effects of up to one year with intraprostatic botulinum toxin type A injection on LUTS and quality of life in BPH patients. J Urol 2006;175(4 suppl):464.

Smith CP, Chancellor MB: Emerging Role of botulinum toxin in the treatment of voiding dysfunction. J Urol 2004, 171:2128-2137.

AUA Practice Guidelines Committee: AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendation. J Urol 2003;170:530–547.

Andersen JT, Nickel C, Marshall VR, et al: Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia. Urology 1997;49:839–845.

Ventura S, Pennefather J, Mitchelson F. Cholinergic innervation and function in the prostate gland. Pharmacol Ther 2002;94:93-112.

Coffield JA, Considine RV, Simpson LL.the site and mechanism of action of botulinum neurotoxin. In Jankovic J, Hallet M, editors. Therapy with botulinum Toxin. New York: Marcel Dekker;1994;p.3-13.

Pennefather JN, Lau WAK, Mitchelson F, Ventura S. The autonomic and sensory innervation of the smooth muscle of the prostate gland: a review of pharmacological and histological studies. J Auton Pharmacol 2000;20:193–206.

Lepor H. The pathophysiology of lower urinary tract symptoms in the ageing male population. Br J Urol 1998; 81 (Suppl. 1):29–33.

Ravindranath N, Wion D, Brachet P, Djakiew D. Epidermal growth factor modulates the expression of vascular endothelial growth factor in the human prostate. J Androl 2001;22:432–43.